FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197781843> ?p ?o ?g. }

• W3197781843 endingPage "4480" @default.
• W3197781843 startingPage "4480" @default.
• W3197781843 abstract "Emerging data suggest suboptimal antibody responses to COVID-19 vaccination in patients with hematological malignancies. We evaluated the humoral response following the BNT162b2 vaccine in patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), and Hodgkin’s lymphoma (HL). An FDA-approved, ELISA-based methodology was implemented to evaluate the titers of neutralizing antibodies (NAbs) against SARS-CoV-2 on day 1 of the first vaccine, and afterwards on day 22 and 50. One hundred and thirty-two patients with CLL/lymphomas and 214 healthy matched controls vaccinated during the same period, at the same center were enrolled in the study (NCT04743388). Vaccination with two doses of the BNT162b2 vaccine led to lower production of NAbs against SARS-CoV-2 in patients with CLL/lymphomas compared with controls both on day 22 and on day 50 (p < 0.001 for all comparisons). Disease-related immune dysregulation and therapy-related immunosuppression are involved in the low humoral response. Importantly, active treatment with Rituximab, Bruton’s tyrosine kinase inhibitors, or chemotherapy was an independent prognostic factor for suboptimal antibody response. Patients with HL showed superior humoral responses to the NHL/CLL subgroups. In conclusion, patients with CLL/lymphomas have low humoral response following COVID-19 vaccination, underlining the need for timely vaccination ideally during a treatment-free period and for continuous vigilance on infection control measures." @default.
• W3197781843 created "2021-09-13" @default.
• W3197781843 creator A5010521973 @default.
• W3197781843 creator A5018522443 @default.
• W3197781843 creator A5020431685 @default.
• W3197781843 creator A5033573338 @default.
• W3197781843 creator A5033750115 @default.
• W3197781843 creator A5034053858 @default.
• W3197781843 creator A5036299617 @default.
• W3197781843 creator A5038570947 @default.
• W3197781843 creator A5040387230 @default.
• W3197781843 creator A5041407463 @default.
• W3197781843 creator A5053764173 @default.
• W3197781843 creator A5060469336 @default.
• W3197781843 creator A5063893663 @default.
• W3197781843 creator A5067046406 @default.
• W3197781843 creator A5068927620 @default.
• W3197781843 creator A5078995254 @default.
• W3197781843 creator A5088691462 @default.
• W3197781843 creator A5090511737 @default.
• W3197781843 date "2021-09-06" @default.
• W3197781843 modified "2023-10-16" @default.
• W3197781843 title "Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study" @default.
• W3197781843 cites W1891620832 @default.
• W3197781843 cites W2009794436 @default.
• W3197781843 cites W2050974188 @default.
• W3197781843 cites W2072395096 @default.
• W3197781843 cites W2073414325 @default.
• W3197781843 cites W2153485954 @default.
• W3197781843 cites W2509761270 @default.
• W3197781843 cites W2730462468 @default.
• W3197781843 cites W2738331494 @default.
• W3197781843 cites W2770618238 @default.
• W3197781843 cites W2789508123 @default.
• W3197781843 cites W2800217365 @default.
• W3197781843 cites W3001118548 @default.
• W3197781843 cites W3009335299 @default.
• W3197781843 cites W3009912996 @default.
• W3197781843 cites W3012320055 @default.
• W3197781843 cites W3023300354 @default.
• W3197781843 cites W3028330817 @default.
• W3197781843 cites W3031584350 @default.
• W3197781843 cites W3033388352 @default.
• W3197781843 cites W3036209162 @default.
• W3197781843 cites W3040995557 @default.
• W3197781843 cites W3041007898 @default.
• W3197781843 cites W3042183476 @default.
• W3197781843 cites W3043131535 @default.
• W3197781843 cites W3044482768 @default.
• W3197781843 cites W3045925312 @default.
• W3197781843 cites W3048259261 @default.
• W3197781843 cites W3069281433 @default.
• W3197781843 cites W3081513395 @default.
• W3197781843 cites W3093367571 @default.
• W3197781843 cites W3093729476 @default.
• W3197781843 cites W3096680486 @default.
• W3197781843 cites W3097738396 @default.
• W3197781843 cites W3110244214 @default.
• W3197781843 cites W3110345422 @default.
• W3197781843 cites W3111255098 @default.
• W3197781843 cites W3119591726 @default.
• W3197781843 cites W3131543595 @default.
• W3197781843 cites W3132689925 @default.
• W3197781843 cites W3134757598 @default.
• W3197781843 cites W3135447911 @default.
• W3197781843 cites W3146538993 @default.
• W3197781843 cites W3153280867 @default.
• W3197781843 cites W3156866359 @default.
• W3197781843 cites W3161532590 @default.
• W3197781843 cites W3163785571 @default.
• W3197781843 cites W3163794531 @default.
• W3197781843 cites W3163931433 @default.
• W3197781843 cites W3164070923 @default.
• W3197781843 cites W3164979578 @default.
• W3197781843 cites W3165390631 @default.
• W3197781843 cites W3175995708 @default.
• W3197781843 cites W3176552995 @default.
• W3197781843 cites W3187511802 @default.
• W3197781843 cites W3190687233 @default.
• W3197781843 cites W3200273570 @default.
• W3197781843 doi "https://doi.org/10.3390/cancers13174480" @default.
• W3197781843 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8430746" @default.
• W3197781843 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34503290" @default.
• W3197781843 hasPublicationYear "2021" @default.
• W3197781843 type Work @default.
• W3197781843 sameAs 3197781843 @default.
• W3197781843 citedByCount "39" @default.
• W3197781843 countsByYear W31977818432021 @default.
• W3197781843 countsByYear W31977818432022 @default.
• W3197781843 countsByYear W31977818432023 @default.
• W3197781843 crossrefType "journal-article" @default.
• W3197781843 hasAuthorship W3197781843A5010521973 @default.
• W3197781843 hasAuthorship W3197781843A5018522443 @default.
• W3197781843 hasAuthorship W3197781843A5020431685 @default.
• W3197781843 hasAuthorship W3197781843A5033573338 @default.
• W3197781843 hasAuthorship W3197781843A5033750115 @default.
• W3197781843 hasAuthorship W3197781843A5034053858 @default.
• W3197781843 hasAuthorship W3197781843A5036299617 @default.

• next